Linked Life Data

18639972

Source:http://linkedlifedata.com/resource/pubmed/id/18639972

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-7-29
pubmed:abstractText
The Prostate Cancer Prevention Trial (PCPT) has challenged the validity of recommended prostate-specific antigen (PSA) thresholds for prostate biopsy (> 2.5 ng/ml) given the 17% prostate cancer (pCA) detection rate at PSA of 1.1-2.0. The outcome of patients treated at PSA < or = 2.5 is poorly defined, and advantages associated with such an early diagnosis are uncertain.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1873-7560
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
610-6
pubmed:dateRevised
2010-10-27
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
pubmed:affiliation
Section of Urologic Oncology, Glickman Urological and Kidney Institute, Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195-0001, USA. stephea2@ccf.org [corrected]
pubmed:publicationType
Journal Article